JP2017534583A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017534583A5 JP2017534583A5 JP2017515756A JP2017515756A JP2017534583A5 JP 2017534583 A5 JP2017534583 A5 JP 2017534583A5 JP 2017515756 A JP2017515756 A JP 2017515756A JP 2017515756 A JP2017515756 A JP 2017515756A JP 2017534583 A5 JP2017534583 A5 JP 2017534583A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- subject
- inhibitor
- gap junction
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 95
- 229940122194 Gap junction inhibitor Drugs 0.000 claims description 87
- 206010028980 Neoplasm Diseases 0.000 claims description 71
- 201000011510 cancer Diseases 0.000 claims description 66
- 239000003112 inhibitor Substances 0.000 claims description 43
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 42
- RFCBNSCSPXMEBK-INFSMZHSSA-N c-GMP-AMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]3[C@@H](O)[C@H](N4C5=NC=NC(N)=C5N=C4)O[C@@H]3COP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 RFCBNSCSPXMEBK-INFSMZHSSA-N 0.000 claims description 39
- 206010059282 Metastases to central nervous system Diseases 0.000 claims description 31
- 102100034941 Protocadherin-7 Human genes 0.000 claims description 31
- 101710141460 Protocadherin-7 Proteins 0.000 claims description 31
- 239000002246 antineoplastic agent Substances 0.000 claims description 28
- 102000001045 Connexin 43 Human genes 0.000 claims description 27
- 108010069241 Connexin 43 Proteins 0.000 claims description 27
- 210000004027 cell Anatomy 0.000 claims description 24
- 210000004556 brain Anatomy 0.000 claims description 20
- 206010006187 Breast cancer Diseases 0.000 claims description 14
- 208000026310 Breast neoplasm Diseases 0.000 claims description 14
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 14
- 190000008236 carboplatin Chemical group 0.000 claims description 14
- 229960004562 carboplatin Drugs 0.000 claims description 14
- 201000005202 lung cancer Diseases 0.000 claims description 14
- 208000020816 lung neoplasm Diseases 0.000 claims description 14
- 230000001225 therapeutic effect Effects 0.000 claims description 14
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical group CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 claims description 13
- 229940013798 meclofenamate Drugs 0.000 claims description 13
- 102000010970 Connexin Human genes 0.000 claims description 12
- 108050001175 Connexin Proteins 0.000 claims description 12
- 210000003976 gap junction Anatomy 0.000 claims description 12
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 10
- 230000002401 inhibitory effect Effects 0.000 claims description 9
- 230000004083 survival effect Effects 0.000 claims description 9
- 230000001394 metastastic effect Effects 0.000 claims description 8
- 206010027476 Metastases Diseases 0.000 claims description 7
- 230000012010 growth Effects 0.000 claims description 7
- 208000037819 metastatic cancer Diseases 0.000 claims description 7
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims description 7
- 230000009401 metastasis Effects 0.000 claims description 6
- 210000004881 tumor cell Anatomy 0.000 claims description 5
- 230000005764 inhibitory process Effects 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 230000002452 interceptive effect Effects 0.000 claims description 2
- 230000004614 tumor growth Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 98
- 238000002560 therapeutic procedure Methods 0.000 claims 4
- 230000009286 beneficial effect Effects 0.000 claims 1
- 238000003556 assay Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462052966P | 2014-09-19 | 2014-09-19 | |
| US62/052,966 | 2014-09-19 | ||
| PCT/US2015/051057 WO2016044790A1 (en) | 2014-09-19 | 2015-09-18 | Methods for treating brain metastasis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017534583A JP2017534583A (ja) | 2017-11-24 |
| JP2017534583A5 true JP2017534583A5 (enExample) | 2018-10-25 |
| JP6898848B2 JP6898848B2 (ja) | 2021-07-07 |
Family
ID=55533931
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017515756A Active JP6898848B2 (ja) | 2014-09-19 | 2015-09-18 | 脳転移を治療するための方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US10413522B2 (enExample) |
| EP (2) | EP3685832B1 (enExample) |
| JP (1) | JP6898848B2 (enExample) |
| CN (1) | CN107106544B (enExample) |
| AU (3) | AU2015317330B2 (enExample) |
| CA (1) | CA2961894C (enExample) |
| WO (1) | WO2016044790A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107106544B (zh) * | 2014-09-19 | 2021-09-24 | 纪念斯隆-凯特琳癌症中心 | 用于治疗脑转移瘤的方法 |
| CN107290438B (zh) * | 2016-03-31 | 2020-10-16 | 深圳翰宇药业股份有限公司 | 一种多肽有关物质的高效液相色谱分析方法 |
| WO2019014246A1 (en) * | 2017-07-10 | 2019-01-17 | Cantley Lewis C | TARGETING CHROMOSOMIC INSTABILITY AND SIGNALING OF CYTOSOLIC DNA IN AVAL FOR THE TREATMENT OF CANCER |
| AU2018314234B2 (en) * | 2017-08-11 | 2024-10-24 | Board Of Regents, The University Of Texas System | Targeting kinases for the treatment of cancer metastasis |
| US11717506B2 (en) | 2019-05-07 | 2023-08-08 | The Johns Hopkins University | Neuroprotective compounds for amyotrophic lateral sclerosis |
| WO2021051015A1 (en) * | 2019-09-13 | 2021-03-18 | Auckland Uniservices Limited | Compositions and methods for rescuing retinal and choroidal structure and function |
| CN111420025B (zh) * | 2020-04-28 | 2021-06-11 | 中国药科大学 | 茜草科类型环肽化合物在制备cGAS-STING信号通路激活剂的药物中的应用 |
| GB202014831D0 (en) | 2020-09-21 | 2020-11-04 | Dc Europa Ltd | Disconnection agents |
| US12306192B2 (en) * | 2021-02-08 | 2025-05-20 | Cedars-Sinai Medical Center | Method of detecting cognitive impairment |
| CN114252324B (zh) * | 2022-03-02 | 2022-05-13 | 中国人民解放军军事科学院军事医学研究院 | 一种方便使用的多孔脑片孵育装置 |
| WO2024020491A1 (en) * | 2022-07-20 | 2024-01-25 | The University Of North Carolina At Chapel Hill | Methods of treating cancer of the central nervous system comprising 5-ethynyl-2'-deoxyuridine |
| WO2025024284A1 (en) * | 2023-07-21 | 2025-01-30 | The Board Of Regents Of The University Of Texas System | Monoclonal antibodies against pcdh7 for lung cancer therapy |
| CN117298143A (zh) * | 2023-10-11 | 2023-12-29 | 广州医科大学附属第一医院（广州呼吸中心） | β葡聚糖在制备治疗肺癌脑转移瘤药物中的应用 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9411635D0 (en) | 1994-06-10 | 1994-08-03 | Smithkline Beecham Plc | Novel treatment |
| JPH10501256A (ja) | 1994-06-10 | 1998-02-03 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | Ｃ−４アミド置換化合物およびその治療剤としての使用 |
| AU740588B2 (en) | 1997-11-24 | 2001-11-08 | Scripps Research Institute, The | Inhibitors of gap junction communication |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| AUPP249298A0 (en) | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
| US6566131B1 (en) | 2000-10-04 | 2003-05-20 | Isis Pharmaceuticals, Inc. | Antisense modulation of Smad6 expression |
| US6410323B1 (en) | 1999-08-31 | 2002-06-25 | Isis Pharmaceuticals, Inc. | Antisense modulation of human Rho family gene expression |
| US6251931B1 (en) | 1998-11-24 | 2001-06-26 | The Scripps Research Institute | Inhibitors of gap junction communication |
| US6107091A (en) | 1998-12-03 | 2000-08-22 | Isis Pharmaceuticals Inc. | Antisense inhibition of G-alpha-16 expression |
| US5981732A (en) | 1998-12-04 | 1999-11-09 | Isis Pharmaceuticals Inc. | Antisense modulation of G-alpha-13 expression |
| US6046321A (en) | 1999-04-09 | 2000-04-04 | Isis Pharmaceuticals Inc. | Antisense modulation of G-alpha-i1 expression |
| US6770633B1 (en) | 1999-10-26 | 2004-08-03 | Immusol, Inc. | Ribozyme therapy for the treatment of proliferative skin and eye diseases |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| AU2001245793A1 (en) | 2000-03-16 | 2001-09-24 | Cold Spring Harbor Laboratory | Methods and compositions for rna interference |
| US6365354B1 (en) | 2000-07-31 | 2002-04-02 | Isis Pharmaceuticals, Inc. | Antisense modulation of lysophospholipase I expression |
| US6566135B1 (en) | 2000-10-04 | 2003-05-20 | Isis Pharmaceuticals, Inc. | Antisense modulation of caspase 6 expression |
| US7632866B2 (en) | 2002-10-21 | 2009-12-15 | Ramot At Tel Aviv University | Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators |
| EP1582219A4 (en) | 2002-11-29 | 2007-11-28 | Japan Science & Tech Agency | CONNEXIN 26 INHIBITORS AND INHIBITORS OF TUMORMETASTASES |
| KR20060054405A (ko) * | 2003-07-31 | 2006-05-22 | 더 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 암, 암의 발병 또는 암 증상의 치료, 예방 및/또는 개선용조성물 및 방법 |
| ES2766549T3 (es) | 2005-02-03 | 2020-06-12 | Coda Therapeutics Ltd | Compuestos anticonexina 43 para el tratamiento de heridas crónicas |
| US7704946B2 (en) | 2006-05-05 | 2010-04-27 | Caritas St. Elizabeth's Medical Center | Reversible inhibition of pyramidal gap junction activity |
| CA2710232A1 (en) | 2007-12-21 | 2009-07-09 | Coda Therapeutics, Inc. | Treatment of abnormal or excessive scars |
| CA2726878A1 (en) * | 2008-06-05 | 2009-12-10 | Minster Research Limited | Novel treatments |
| EP2331093A4 (en) * | 2008-08-27 | 2016-06-01 | Univ Columbia | COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING TOXICITY AND TREATMENT PREVENTING DISEASES |
| FR2935611B1 (fr) * | 2008-09-10 | 2010-10-15 | Commissariat Energie Atomique | Utilisation d'agents anti-connexines pour moduler l'effet therapeutique de molecules psychotropes |
| US20110262442A1 (en) * | 2009-11-06 | 2011-10-27 | Adenios, Inc. | Compositions for treating cns disorders |
| AU2010325755A1 (en) | 2009-12-03 | 2012-06-21 | Proximagen Ltd | Treatment of infectious diseases |
| JP2013512887A (ja) * | 2009-12-03 | 2013-04-18 | プロキシマゲン リミテッド | 感染症の治療 |
| WO2014129914A1 (en) * | 2013-02-22 | 2014-08-28 | Auckland Uniservices Limited | Methods of treatment |
| CA2908154C (en) * | 2013-04-29 | 2023-11-28 | Memorial Sloan Kettering Cancer Center | Compositions and methods for altering second messenger signaling |
| EP3057977A4 (en) | 2013-10-15 | 2017-07-26 | President and Fellows of Harvard College | Methods and compositions for eradicating leukemic cells |
| CN107106544B (zh) * | 2014-09-19 | 2021-09-24 | 纪念斯隆-凯特琳癌症中心 | 用于治疗脑转移瘤的方法 |
-
2015
- 2015-09-18 CN CN201580063121.3A patent/CN107106544B/zh active Active
- 2015-09-18 EP EP19206911.0A patent/EP3685832B1/en active Active
- 2015-09-18 WO PCT/US2015/051057 patent/WO2016044790A1/en not_active Ceased
- 2015-09-18 EP EP15842612.2A patent/EP3193865B1/en active Active
- 2015-09-18 JP JP2017515756A patent/JP6898848B2/ja active Active
- 2015-09-18 CA CA2961894A patent/CA2961894C/en active Active
- 2015-09-18 AU AU2015317330A patent/AU2015317330B2/en active Active
-
2017
- 2017-03-17 US US15/462,253 patent/US10413522B2/en active Active
-
2019
- 2019-09-13 US US16/570,180 patent/US11058665B2/en active Active
-
2021
- 2021-04-14 AU AU2021202257A patent/AU2021202257B2/en active Active
- 2021-06-11 US US17/345,572 patent/US12029717B2/en active Active
-
2023
- 2023-08-23 AU AU2023219864A patent/AU2023219864A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017534583A5 (enExample) | ||
| Taylor-Harding et al. | Cyclin E1 and RTK/RAS signaling drive CDK inhibitor resistance via activation of E2F and ETS | |
| EA201992220A1 (ru) | Комбинированная терапия для лечения или предупреждения опухолей | |
| PH12021552497A1 (en) | Enzyme inhibitors | |
| PH12020500203A1 (en) | Identification of lkb1 mutation as a predictive boimarker for sensitivity to tor kinase inhibitors | |
| WO2020093006A8 (en) | Methods of treating cancer in biomarker-identified patients with non-covalent inhibitors of cyclin-dependent kinase 7 (cdk7) | |
| EA201100425A1 (ru) | Производные пиколинамида в качестве ингибиторов киназы | |
| PH12017502391A1 (en) | Compositions and methods for inhibiting arginase activity | |
| PH12018500642A1 (en) | Anti-garp antibody | |
| MX2016017288A (es) | Metodos para tratar el cancer con inhibidores de tigit y agentes contra el cancer. | |
| MX2021008610A (es) | Tratamiento del cancer usando combinaciones de inhibidores de erk y raf. | |
| MX2017005929A (es) | Terapia de combinacion con agonistas de unión ox40 e inhibidores de tigit. | |
| MX2021007651A (es) | Inhibidores de ezh2 para tratar linfomas. | |
| MX2010005768A (es) | Composiciones y métodos para inhibir la activación del arnbc-dependiente de la proteina de la kinasa y la inhibición del crecimiento tumoral. | |
| ATE525375T1 (de) | Hemmer von janus-kinasen und/oder 3- phosphoinositid-abhängiger protein-kinase 1 | |
| EA201791946A1 (ru) | Лечение хронической реакции "трансплантат против хозяина" с применением ингибиторов syk | |
| MX2018006781A (es) | Inhibidores de mat2a para el tratamiento del cancer que no expresen mtap. | |
| JP2015504847A5 (enExample) | ||
| MY199395A (en) | Selective inhibitor of exon 20 insertion mutant egfr | |
| SA520420909B1 (ar) | تثبيط بروتين رابط لـ creb (cbp) | |
| Chan et al. | PLCɛ and the RASSF family in tumour suppression and other functions | |
| Yeung et al. | K‐Ras mutation and amplification status is predictive of resistance and high basal pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell lines | |
| Schaefer et al. | The small-molecule kinase inhibitor D11 counteracts 17-AAG-mediated up-regulation of HSP70 in brain cancer cells | |
| PH12014500536A1 (en) | Compositions and methods for treating cancer using pi3k beta inhibitor and mapk pathway inhibitor, including mek and raf inhibitors | |
| JP2019512021A5 (enExample) |